| 2003P-0029 - Use of Ozone-Depleting Substances; Removal of Essential-Use Designations (Albuterol) | |||||||||||||||||||||||
| FDA Comment Number : | EC18 | ||||||||||||||||||||||
| Submitter : | Mr. ED BOYD | Date & Time: | 07/19/2004 05:07:51 | ||||||||||||||||||||
| Organization : | CONSUMER'S PHARMACY | ||||||||||||||||||||||
| Health Professional | |||||||||||||||||||||||
| Category : | |||||||||||||||||||||||
| Issue Areas/Comments | |||||||||||||||||||||||
| GENERAL | |||||||||||||||||||||||
| GENERAL | |||||||||||||||||||||||
| I AM AGAINST THIS PROPOSAL. THE ECCONOMIC IMPACT ON HEALTH CARE WOULD BE UNNECESSARILY INCREASED. PROVENTIL HFA IS A DRUG PRODUCT THAT CONFORMS TO THE PROPOSAL AND COSTS MY PATIENTS $47.80. ALBUTEROL INHALER IS A DRUG PRODUCT THAT CONTAINS THE SAME ACTIVE INGREDIENT BUT DOES NOT CONFORM TO THE PROPOSAL AND COSTS MY PATIENTS $16.40. | |||||||||||||||||||||||